AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A platelet aggregation inhibitor comprising a quinolone derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:



(I)

[the symbols in the formula have the following meanings:

X: C-R^7 or N;

Y: C-R^6 or N;

R^{11}: -H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted;

R^{12}: -H, or a lower alkyl or an aryl which respectively may be substituted, provided that R^{11} and R^{12} together with the adjacent nitrogen may form a cyclic amino which may be substituted;

R^2: a lower alkyl, a cycloalkyl, an aryl or a hetero ring, which respectively may be substituted;

R^3: a halogen, a lower alkyl or -O-lower alkyl;

R^4: a cycloalkyl or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl; provided that when R4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH;

R^5: -H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, -O-lower alkyl, -OH, -NHCO-lower alkyl, -N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted;
R^6: -H, a halogen, a lower alkyl or a halogeno-lower alkyl;
R^7: -H, a halogen, a lower alkyl or a halogeno-(lower alkyl);
provided that when Y represents C-R^6, R^2 and R^6 together may form a lower alkylene or a lower alkenylene.

2. (original): A P2Y12 inhibitor comprising the compound according to claim 1 as an active ingredient.

3. (withdrawn and currently amended): A method for inhibiting platelet aggregation in an individual, comprising administering a therapeutically effective amount of the compound of ~~Use of the compound according to~~ claim 1, ~~as a platelet aggregation inhibitor~~and at least one pharmaceutically acceptable carrier, to the individual.

4. (withdrawn and currently amended): A method for inhibiting P2Y12 in an individual, comprising administering a therapeutically effective amount of the compound of ~~Use of the compound according to~~ claim 1, and at least one pharmaceutically acceptable carrier, to the individual~~as a P2Y12 inhibitor~~.

5 - 6. (canceled).

7. (original): A quinolone derivative represented by the formula (I-a) or a pharmaceutically acceptable salt thereof:



(I-a)

[the symbols in the formula have the following meanings:

X: C-R^7 or N;

Y: C-R^6 or N;

R^{11}: -H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted;

R^{12}: -H, or a lower alkyl or an aryl, which respectively may be substituted, provided that R^{11} and R^{12} together with the adjacent nitrogen may form a cyclic amino which may be substituted;

R^2: a lower alkyl, a cycloalkyl, an aryl or a hetero ring, which respectively may be substituted;

R^3: a halogen, a lower alkyl or -O-lower alkyl;

R^4: a cycloalkyl or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl; provided that wherein R^4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH;

R^5: -H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, -O-lower alkyl, -OH, -NHCO-lower alkyl, -N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted;

R^6: -H, a halogen, a lower alkyl or a halogeno-lower alkyl;

R^7: -H, a halogen, a lower alkyl or a halogeno-(lower alkyl);

provided that when Y represents C-R^6, R^2 and R^6 together may form a lower alkylene or a lower alkenylene and provided that 7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbohydrazide is excluded.

8. (original): The compound according to claim 7, wherein X is CH.

9. (original): The compound according to claim 8, wherein R^3 is a halogen.

10. (original): The compound according to claim 9, wherein R^4 is a cycloalkyl.

11. (original): The compound according to claim 10, wherein R^5 is -H, -OH or a halogen.

12. (currently amended): The compound according to claim 11, wherein R^{12} is a lower alkyl ~~respectively~~ substituted with one or more substituent groups selected from ~~the~~ Group Q, ~~(provided that at~~ wherein at least one of the substituent groups is selected from~~is substituted with a group of the~~ Group P~~)~~:
Group P: $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$; and
Group Q: -F, -OH, $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$

13. (withdrawn and currently amended): The compound according to claim 11, wherein $NR^{11}R^{12}$ together is a cyclic amino group substituted with one or more substituent groups selected from ~~the~~ Group Q, ~~(provided that~~wherein at least one of the substituent groups ~~is substituted with a group of the~~ is selected from Group P~~)~~:
Group P: $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$; and
Group Q: -F, -OH, $-CO_2H$, $-SO_3H$, $-P(O)(OH)_2$, and $-OP(O)(OH)_2$.

14. (original): The compound according to claim 7, which is [2-({ [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1 ,4-dihydroquinolin-3-yl]carbonyl} amino)ethyl]phosphonic acid,

(2S)-2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)butanedioic acid,

2-({[7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl dihydrogen phosphate,

(2S)-2-({ [7-(cyclohexylamino)-1-cyclopentyl-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)pentanedioic acid,

{ 2-[({[7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3S)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3 yl}carbonyl)amino]ethyl}phosphonic acid,

{2-[({7-(cyclohexylamino)-6-fluoro-4-oxo-1-[(3R)-tetrahydrofuran-3-yl]-1,4-dihydroquinolin-3-yl}carbonyl)amino] ethyl}phosphonic acid,

[2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)-1,1-difluoroethyl]phosphonic acid,

{2-[({7-(cyclohexylamino)-6-fluoro-l-[2-hydroxy-l-(hydroxymethyl)ethyl]-4-oxo-1,4dihydroquinolin-3-yl}carbonyl)amino)ethyl}phosphonic acid,

[2-({[7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl} amino)ethyl]phosphonic acid,

[2-({ [7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-l ,4-dihydrocinnolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,

[2-({ [7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid,

(2S)-2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)pentanedioic acid,

(2S)-2-({[7-(cyclohexylamino)-1-(1-ethylpropyl)-6-fluoro-4-oxo-1,4-dihydrocinnolin-3-yl]carbonyl}amino)pentanedioic acid or

[2-({ [7-(cyclohexylamino)-1-(2,2-dimethyl-l ,3-dioxan-5-yl)-6-fluoro-4-oxo-1,4-dihydroquinolin-3-yl]carbonyl}amino)ethyl]phosphonic acid, or a pharmaceutically acceptable salt thereof.

15. (currently amended): ~~The~~ A pharmaceutical composition comprising a compound according to any one of claims 7 through 14 and a pharmaceutically acceptable carrier.

16. (original): The pharmaceutical composition according to claim 15, which is a platelet aggregation inhibitor.

17. (original): The pharmaceutical composition according to claim 15, which is a P2Y12 inhibitor.

18. (withdrawn and currently amended): A method for inhibiting platelet aggregation in an individual, comprising administering a therapeutically effective amount of the compound of ~~Use of the compound according to~~ any one of claims 7 through 14 ~~as a platelet aggregation inhibitor~~, and at least one pharmaceutically acceptable carrier, to the individual.

19. (withdrawn and currently amended): A method for inhibiting P2Y12 in an individual, comprising administering a therapeutically effective amount of the compound of ~~Use of the compound according to~~ any one of claims 7 through 14, and at least one pharmaceutically acceptable carrier, to the individual ~~as a P2Y12 inhibitor~~.

20 - 21. (canceled).